No. of Pages: 109 | Report Code: TIPRE00022062 | Category: Life Sciences
Le syndrome du côlon irritable (SCI) est défini comme un trouble gastro-intestinal provoquant une gêne à l\'estomac, ainsi qu\'un vent, diarrhée et constipation. Le SCI peut se développer après une grave séance de diarrhée (gastro-entérite) causée par une bactérie ou un virus. Les personnes exposées à des événements stressants, en particulier pendant l’enfance, ont tendance à présenter davantage de symptômes du SCI. Le diagnostic du SCI est effectué à partir des antécédents médicaux, d\'un examen physique et de tests d\'imagerie.
Le marché nord-américain du diagnostic du syndrome du côlon irritable (SCI) devrait atteindre 1 529,08 millions de dollars américains d\'ici 2028, contre 950,83 millions de dollars américains en 2020 ; on estime qu’il croîtra à un TCAC de 6,2 % de 2021 à 2028. La croissance du marché est déterminée en raison de certains des principaux facteurs déterminants, tels que la prévalence croissante du syndrome du côlon irritable et des affections associées et les progrès dans le diagnostic du syndrome. D\'un autre côté, les défis liés au diagnostic du SCI sont susceptibles de freiner la croissance du marché au cours des années de prévision.
Sur la base du diagnostic, le marché nord-américain du diagnostic du syndrome du côlon irritable (SCI) a été segmenté en tests de laboratoire et en imagerie. essais. En 2020, le segment des tests de laboratoire détenait une part de marché plus importante et devrait connaître une croissance plus rapide au cours des années à venir.
Sur la base d\'indications, l\'Amérique du Nord est irritable. Le marché du diagnostic du syndrome intestinal (SCI) est segmenté en douleurs et crampes, diarrhée, constipation et alternance de constipation et de crampes. diarrhée. Le segment de la douleur et des crampes détenait la plus grande part du marché en 2020 et devrait enregistrer le TCAC le plus élevé du marché au cours de la période de prévision.
Quelques-unes des sources primaires et secondaires associées à ce rapport sur l\'Amérique du Nord Le marché du diagnostic du syndrome du côlon irritable (SCI) sont l\'American Society for Gastrointestinal Endoscopy (ASGE), les Centers for Disease Control and Prevention (CDC) et la Fondation internationale pour les troubles gastro-intestinaux (IFFGD) .
Strategic insights for North America Irritable Bowel Syndrome (IBS) Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 950.83 Million |
| Market Size by 2028 | US$ 1,529.08 Million |
| Global CAGR (2021 - 2028) | 6.2% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2028 |
| Segments Covered |
By Diagnostic
|
| Regions and Countries Covered | Amérique du Nord
|
| Market leaders and key company profiles |
The regional scope of North America Irritable Bowel Syndrome (IBS) Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Irritable Bowel Syndrome (IBS) Diagnostics Market is valued at US$ 950.83 Million in 2020, it is projected to reach US$ 1,529.08 Million by 2028.
As per our report North America Irritable Bowel Syndrome (IBS) Diagnostics Market, the market size is valued at US$ 950.83 Million in 2020, projecting it to reach US$ 1,529.08 Million by 2028. This translates to a CAGR of approximately 6.2% during the forecast period.
The North America Irritable Bowel Syndrome (IBS) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Irritable Bowel Syndrome (IBS) Diagnostics Market report:
The North America Irritable Bowel Syndrome (IBS) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Irritable Bowel Syndrome (IBS) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Irritable Bowel Syndrome (IBS) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Irritable Bowel Syndrome (IBS) Diagnostics Market
